-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Labcorp , a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians ...
The Village Church presents ‘Practicing the Way’ All are invited to register for “Practicing the Way”, a popular eight-week ...
Camino Books on the third level Ocean View Turf Deck at Del Mar Plaza, 1555 Camino Del Mar, Del Mar. The book is described on ...
After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...
Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis New study will investigate potential of BI 765423 to improve lung function for patients ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patientsIngelheim, ...
Personal Independence Payment (PIP) is a disability benefit paid to those with long-term physical or mental health conditions ...
Not intended for US and UK audiences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback